May 17, 2018

Dear [Redacted]

Re: Your request for access to information under Part II of the Access to Information and Protection of Privacy Act, our file # TCII/11/2018

On March 20, 2018 the Department of Tourism, Culture, Industry and Innovation received your request for access to the following record:

All correspondence, briefings, and communications produced or received by the Department of Tourism, Culture, Industry and Innovation regarding Sequence Bio and/or ethics approval of any Sequence Bio research studies.

On March 26th, you agreed to narrow the scope by date range to anything from January 1, 2017 to the date of the request (March 20th, 2018).

I am pleased to inform you that a decision has been made by the Deputy Minister for the Department of Tourism, Culture, Industry and Innovation to provide access to some of the requested information. Access to the remaining records, and/or information contained within the records, has been refused in accordance with the following exceptions to disclosure, as specified in the Access to Information and Protection of Privacy Act (the Act):

s.29(1)(a)

Policy advice or recommendations

29. (1) The head of a public body may refuse to disclose to an applicant information that would reveal

(a) advice, proposals, recommendations, analyses or policy options developed by or for a public body or minister;
s. 30(1)(a)(b)

Legal advice

30. (1) The head of a public body may refuse to disclose to an applicant information

(a) that is subject to solicitor and client privilege or litigation privilege of a public body

(b) that would disclose legal opinions provided to a public body by a law officer of the Crown.

s. 31(1)(l)

Disclosure harmful to law enforcement

31. (1) The head of a public body may refuse to disclose information to an applicant where the disclosure could reasonably be expected to (l) reveal the arrangements for the security of property or a system, including a building, a vehicle, a computer system or a communications system;

s.39(1)(a)(ii), 39(b), 39(c)(l)

Disclosure harmful to business interests of a third party

39. (1) The head of a public body shall refuse to disclose to an applicant information

(a) that would reveal

   (i) trade secrets of a third party, or

   (ii) commercial, financial, labour relations, scientific or technical information of a third party;

(b) that is supplied, implicitly or explicitly, in confidence; and

(c) the disclosure of which could reasonably be expected to

   (i) harm significantly the competitive position or interfere significantly with the negotiating position of the third party,

   (ii) result in similar information no longer being supplied to the public body when it is in the public interest that similar information continue to be supplied,

   (iii) result in undue financial loss or gain to any person, or

   (iv) reveal information supplied to, or the report of, an arbitrator, mediator, labour relations officer or other person or body appointed to resolve or inquire into a labour relations dispute.
Disclosure harmful to personal privacy

40. (1) The head of a public body shall refuse to disclose personal information to an applicant where the disclosure would be an unreasonable invasion of a third party's personal privacy.

Conflict with other Acts

7. (2) notwithstanding subsection (1), where access to a record is prohibited or restricted by, or the right to access a record is provided in a provision designated in Schedule A, that provision shall prevail over this Act or a regulation made under it. Schedule A (p) section 21 of the Research and Development Council Act;

s. 21 (1)(b) of RDC Act

Records of commercially sensitive information

21. (1) Notwithstanding section 7 of the Access to Information and Protection of Privacy Act, 2015, in addition to the information that shall or may be refused under Part II, Division 2 of that Act, the chief executive officer, or the head of another public body,

(b) shall refuse to disclose to an applicant under that Act commercially sensitive information of a third party

Please be advised that the following pages have been withheld in their entirety under section 39 of ATIPPA and/or section 21 of the Research and Development Council Act:

- pp. 25 – 38 Section 39 ATIPPA
- pp. 123 – 192 Section 21 of the Research and Development Council Act
- pp. 193 – 198 Section 39 ATIPPA and Section 21 of the Research and Development Council Act
- pp. 199 – 205 Section 21 of the Research and Development Council Act
- pp. 217 – 222 Section 21 of the Research and Development Council Act
- pp. 240 - Section 21 of the Research and Development Council Act
- pp. 242 – 289 Section 21 of the Research and Development Council Act
- pp. 306 – 333 Section 21 of the Research and Development Council Act

As required by 8(2) of the Act, we have severed information that is unable to be disclosed and have provided you with as much information as possible. In accordance with your request for a copy of the records, the appropriate copies have been enclosed.

Please be advised that you may appeal this decision and ask the Information and Privacy Commissioner to review the decision to provide partial access to the requested information, as set out in section 42 of the Act (a copy of this section of the Act has been enclosed for your reference). A request to the Commissioner must be made in writing within 15 business days of the date of this letter or within a longer period that may be allowed by the Commissioner. Your appeal should identify your concerns with the request and why you are submitting the appeal.
The appeal may be addressed to the Information and Privacy Commissioner as follows:

Office of the Information and Privacy Commissioner
2 Canada Drive
P. O. Box 13004, Stn. A
St. John’s, NL A1B 3V8
Telephone: (709) 729-6309
Toll-Free: 1-877-729-6309
Facsimile: (709) 729-6500

You may also appeal directly to the Supreme Court Trial Division within 15 business days after you receive the decision of the public body, pursuant to section 52 of the Act.

Please be advised that responsive records will be published following a 72 hour period after the response is sent electronically to you or five business days in the case where records are mailed to you. It is the goal to have the responsive records posted to the Office of Public Engagement's website within one business day following the applicable period of time. Please note that requests for personal information will not be posted online.

If you have any further questions, please feel free to contact me phone at (709) 729-7246 or by e-mail at heatherbrown@gov.nl.ca

Sincerely,

[Signature]

Heather Brown
ATIPP Coordinator
Access or correction complaint

42. (1) A person who makes a request under this Act for access to a record or for correction of personal information may file a complaint with the commissioner respecting a decision, act or failure to act of the head of the public body that relates to the request.

(2) A complaint under subsection (1) shall be filed in writing not later than 15 business days

(a) after the applicant is notified of the decision of the head of the public body, or the date of the act or failure to act; or

(b) after the date the head of the public body is considered to have refused the request under subsection 16 (2).

(3) A third party informed under section 19 of a decision of the head of a public body to grant access to a record or part of a record in response to a request may file a complaint with the commissioner respecting that decision.

(4) A complaint under subsection (3) shall be filed in writing not later than 15 business days after the third party is informed of the decision of the head of the public body.

(5) The commissioner may allow a longer time period for the filing of a complaint under this section.

(6) A person or third party who has appealed directly to the Trial Division under subsection 52 (1) or 53 (1) shall not file a complaint with the commissioner.

(7) The commissioner shall refuse to investigate a complaint where an appeal has been commenced in the Trial Division.

(8) A complaint shall not be filed under this section with respect to

(a) a request that is disregarded under section 21;

(b) a decision respecting an extension of time under section 23;

(c) a variation of a procedure under section 24; or

(d) an estimate of costs or a decision not to waive a cost under section 26.

(9) The commissioner shall provide a copy of the complaint to the head of the public body concerned.
Direct appeal to Trial Division by an applicant

52. (1) Where an applicant has made a request to a public body for access to a record or correction of personal information and has not filed a complaint with the commissioner under section 42, the applicant may appeal the decision, act or failure to act of the head of the public body that relates to the request directly to the Trial Division.

(2) An appeal shall be commenced under subsection (1) not later than 15 business days

(a) after the applicant is notified of the decision of the head of the public body, or the date of the act or failure to act; or

(b) after the date the head of the public body is considered to have refused the request under subsection 16 (2).

(3) Where an applicant has filed a complaint with the commissioner under section 42 and the commissioner has refused to investigate the complaint, the applicant may commence an appeal in the Trial Division of the decision, act or failure to act of the head of the public body that relates to the request for access to a record or for correction of personal information.

(4) An appeal shall be commenced under subsection (3) not later than 15 business days after the applicant is notified of the commissioner’s refusal under subsection 45 (2).
ACCEA is the lead for the Accelerated Disease Agenda.

we have had a number of discussions with

Develop Data Base
- gather sample
- genetic testing

approval required from:
Health Research Ethics Board

> to support research.
> to identify new drug target
> to support drug development.
> to market

Support - Chris Harder

RDC approval
S.39(1)(a)(ii), 39(b), 39(c)(i)

potential collaboration with MUN

Board Members:
- Mark Sobben
- Andrew Farley

Secure platform
S.39(1)(a)(ii), 39(b), 39(c)(i)

Project - 3 focuses

Goal - how do we treat diseases.
Sequence Bio

Bio-tech manufacturing

raising capital series A round $30m
Meeting Note
Department of Health and Community Services
Department of Tourism, Industry and Innovation
Meeting with Sequence Bio Inc.
March 14, 2017
3:00-4:30, TCII Main Boardroom

Attendees:
Chris Gardiner, Acting CEO, SBI
Karen Moores, VP External Affairs, SBI
Dan Brake, Director of Technology, SBI
Jeremy Gruschow, Chief Business Officer, SBI (by phone)
Angela Power, Director Ethics and Privacy, SBI
Neala Quigley, Director of Community Engagement, SBI
John Abbott, Deputy Minister, HCS
Michael Harvey, Assistant Deputy Minister, HCS
Ted Lomond, Deputy Minister, TCII
Marc Killey, Assistant Deputy Minister, TCII
Chantelle MacDonald Newhook, Solicitor, JPS
Meaghan McConnell, Solicitor, JPS
Kirk Youden, Sector Lead, TCII

Purpose of Meeting:
- Sequence Bio Inc. (SBI) has requested a meeting with Departments of Health and Community (HCS) Services and Tourism, Culture, Industry and Innovation (TCII) to provide an update on the company’s activities.

Background:
- SBI, a start-up company based in St. John’s, is proposing a project which will gather genetic samples from 100,000 residents of Newfoundland and Labrador and link it to the datasets of personal health information held by the Newfoundland and Labrador Centre for Health Information (NLCHI). It is not fully known how, if the project is approved, SBI intends to use the data once this linkage is made, other than using it to build a platform to support cohort research, to identify new drug targets, and to support drug development (an overview of SBI business model is attached).

- Approval of the project by the Health Research Ethics Board (HREB) is pending. SBI is currently developing a subsequent submission to the HREB which will provide more detail on the project. The anticipated timing of this is not known, but recent indications from the company are that they are reviewing its timelines and approach moving forward.

- Under the Personal Health Information Act, a custodian (including NLCHI) may disclose personal health information for research, only where the research project has been approved by a HREB or research ethics body under the Health Research Ethics Authority Act. If the HREB approves the project, a separate privacy assessment would be completed by HCS and NLCHI. It is important to note, that the complete business model and scope of any project must first be fully understood before a privacy assessment can be completed.

Develop database to support research, identify new drug targets, support drug development.
Until such time that SBI fully discloses exactly what the company is proposing, officials are unable to provide any recommendations or assessments on its project(s).

- In October 2015, SBI entered into a non-binding support Memorandum of Understanding with the Department of Health and Community Services. HCS and the Department of Tourism, Culture, Industry and Innovation (TCII) have been meeting with SBI representatives. TCII representatives recently met with members of SBI (February 21, 2017). Given the recent changes with the company’s plan, TCII officials recommended the company fully update all stakeholders on its plans moving forward. SBI also indicated they have regular meetings with NLCHI.

- Genetic research by private companies presents both opportunities for emerging health research and challenges in terms of how to protect the public interest and ensure that the province benefits from profits made by companies using NL residents’ genetic and health data resources.

- HCS has established a working group with representatives from the Departments of TCII and JPS to:
  - develop a framework that allows the province to enter into benefits agreements with commercial companies, such as SBI, looking to conduct research involving health data in NL; and,
  - identify policy and legal/legislative mechanisms necessary to protect NL’s health data resources.

- In November 2016, SBI announced the appointment of Chris Gardner as acting Chief Executive Officer, replacing Dr. Tyler Wish. Chris Gardner is a co-founder of the company and previously served as Chief Operating Officer and President. Tyler Wish is no longer with the company or its management. The Board of Directors indicated to the HREA that it would be taking more direct involvement in the company’s management.

- The company is also reviewing its approach moving forward. Recently,

- SBI also made application to the Research Development Corporation (RDC). This application to RDC was recently approved for the development of the core technology platform to support enrollment, data management, and integration processes as well as future research and analytics to support the 100k Initiative.

- The project has three key focus areas for development including: (1) an electronic consent process to give the firm the ability to quickly, properly and effectively obtain consent from 100,000 participants via an informative electronic interface; (2) a bioinformatics platform structure capable of storing and analyzing the massive quantities of highly variable data; and (3) the technology and processes to integrate the ultra large genetic and medical data sets (NLCHI) into the bioinformatics platform.

- The software platform will be required to support the whole process of sample preparation, collection, tracking and integration with technology providers and NLCHI for downstream analysis and discovery. This R&D project is considered Phase I, with the goal of establishing
the data collection methodology and IT platform to support the enrollment of participants and manage their health data. Phase II, which is outside the scope of this project, will focus on the longer-term data collection and analytic capabilities of the IT platform, where SBI can investigate conditions of interest and analyze cohorts of participants. The total project costs for Phase 1 is $1,268,090 of which RDC has approved a $250,000 contribution (maximum allowable under R&D Proof of Concept). The other financial stakeholders are the company and NRC-IRAP.

- The work of SBI may also be affected by the proposed federal Bill S-201, *An Act to prohibit and prevent genetic discrimination.* (SBI recently met with JPS representatives to express support for the Bill.) Bill S-201, was introduced as a Private Member's Senate Bill by (now retired) Senator James Cowan. The Bill has three main components. First, Bill S-201 would enact a new *Genetic Non-Discrimination Act* which would prohibit requiring an individual to undergo a genetic test or to reveal the results of a genetic test as a condition of receiving goods or services or to enter into a contract, with exceptions for medical professionals, and for medical, pharmaceutical and scientific research. Second, the Bill would amend Part III of the *Canada Labour Code* (CLC) to address genetic discrimination in the context of federally regulated employment. Third, the Bill would amend the *Canadian Human Rights Act* (CHRA) to add "genetic characteristics" as a prohibited ground of discrimination.

- Bill S-201 was passed by the Senate with minor amendments and then introduced in the House of Commons. At Second Reading Stage it was referred to the Standing Committee on Justice and Human Rights.

- The federal Minister of Justice and Attorney General submitted a brief to the Standing Committee outlining the Government's position on Bill S-201, indicating that "The Government supports the goals behind Bill S-201, but has some concerns and is not in a position to fully support the approach of the Bill." The federal government supports the proposed amendments to the CHRA, but does not support the two other components of the Bill.

- Currently, Bill S-201 remains at Committee in the House where it will be debated again in March 2017.

**Analysis:**

- The next step in the approvals process following HREB approval is for privacy assessment by HCS and NLCHI. While it appears that the request for HREB approval may be delayed, should HREB approve the project, there may be valid privacy concerns, including the possibility for NL electronic health record data to leave the province.

- The recent application to RDC has to be confirmed by the company.
• A working group around commercial health benefits is continuing its research.

SBI may also argue that a benefits agreement is required in near term.

• Formal negotiations on a benefits agreement should not begin until ethics and privacy requirements have been met; at which point greater clarity on the intentions of the company will be known and then it will be possible to determine when and what form of benefits agreement is required.

• This meeting is essentially intended for the company to update stakeholders and to keep the lines of communication open between HCS, TCII and the SBI. Potential questions for SBI include:

1. We understand you have had a change in management at the CEO level. What implications has this change had on SBI? Can you outline any recent additions/changes?

2. Can you provide an update to current footprint of SBI (how many employees, office, research facilities, data storage).

3. Have there been any changes in focus or scope? What is your central research question? (SBI is currently developing a subsequent submission to the HREB which will provide more detail on the project; can they share any of those details?)

4. What is the current status of the project in terms of HREB approval? What are the next steps for SBI in this process?

5. Is SBI going to complete R&D project prior to moving forward? S.39(1)(a)(ii), 39(b), 39(c)(i)

6. S.39(i)(ii)

7. Can you provide some examples of the types of information you are seeking from the Province (NLCHI)? From participants? Where would this be stored?

8. Have you approached any clinicians in NL regarding research partnerships?

Prepared/Approved by: T. Power/A. Tucker/M. Harvey/K. Youden/M. Kelley
Ministerial Approval: N/A

March 6, 2017
Hi Bill,

Thank you for meeting with us today. We appreciate you taking the time to explain the directive of the accelerated growth program and hear more about Sequence Bio.

In follow up, I have attached a copy of the Sequence Bio: Corporate Overview document. We appreciate the tight timeline and wanted to send along material for your review as quickly as possible. With that said, when the external review of our current financials is completed we will also reach out to you. Security and privacy are core to all we do at Sequence Bio and we will share sensitive information such as this through [redacted]. In the coming days, we will send you [redacted].

Again, it was a pleasure meeting you. Please do not hesitate to contact me if you need anything further or have any questions.

Best,
Neala
Potential copyright material

If you wish to obtain a copy please contact the ATIPP Office at (709) 729-7072 or atippoffice@gov.nl.ca.
Hi Bill,

Thanks again for the update on the Accelerated Growth Program. As mentioned in our telephone meeting, I have attached the updated briefings on the specific areas of Sequence Bio business. As well, I have included a briefing on Genomics Medicine Ireland.

Please let me know if you have any questions.

Best,
Neala

neala quigley
director of community engagement sequence bio
+1.800 298.3480
sequencebio.com
@sequencebio
Potential copyright material

If you wish to obtain a copy please contact the ATIPP Office at (709) 729-7072 or atippoffice@gov.nl.ca.
Hearn, Judith

From: Harvey, Michael
Sent: Tuesday, January 09, 2018 5:42 PM
To: Hearn, Judith; Skinner, Gillian
Subject: Fwd: Meeting request

Judith / Gillian,

Please see below. Which one of you has carriage of the life sciences sector these days. I have always wanted to ensure both depts were represented when we meet with this company. Which one of you should I invite?

Michael

Michael Harvey
Assistant Deputy Minister (Policy, Planning and Performance Monitoring)
Department of Health and Community Services
Government of Newfoundland and Labrador
Tel: 709 729 3103
Cel: 709 693 8570

Begin forwarded message:

From: Neala Quigley <s40 (1)>
Date: January 9, 2018 at 1:44:10 PM NST
To: "Harvey, Michael" <michaelharveynsl.ca>
Subject: Meeting request

Hi Michael,

I hope you had a wonderful (and relaxing) holiday and that 2018 has been treating you well.

I was wondering if you had availability for meeting with Chris Gardner and myself. If it would be easier for your schedule we could come to you. The purpose would be to provide an update on Sequence Bio business matters. Specifically to discuss:

- As well, we are excited to share details about our new Chief Scientific Officer.

Do you have availability next week? Please let me know some preferred times and we can go from there.

Looking forward to speaking with you.

Regards,
Neala
From: Hearn, Judith
Sent: Wednesday, January 10, 2018 8:20 AM
To: Hearn, Judith; Weatherbie, Larry
Cc: Rideout, Lynne
Subject: RE: Meeting request

I think someone from that background should join. Maybe Kirk Youden. We have had dealing before but nothing materialized from BA point of view. Not sure if anyone else has been following client.

Folks,

See Michael Harvey's note below. Have we met with Sequence Bio before? Should Gillian or I join Michael for this meeting?

Larry - Is this one of our identified growth firms?

Judith

Sent from my BlackBerry 10 smartphone on the Bell network.

From: Harvey, Michael <michaelharvey@gov.nl.ca>
Sent: Tuesday, January 9, 2018 5:42 PM
To: Hearn, Judith; Skinner, Gillian
Subject: Fwd: Meeting request

Judith / Gillian,

Please see below. Which one of you has carriage of the life sciences sector these days. I have always wanted to ensure both depts were represented when we meet with this company. Which one of you should I invite?

Michael

Michael Harvey
Assistant Deputy Minister (Policy, Planning and Performance Monitoring)
Department of Health and Community Services
Government of Newfoundland and Labrador
Tel: 709 729 3103
Cel: 709 693 8570

Begin forwarded message:
Hi Michael,

I hope you had a wonderful (and relaxing) holiday and that 2018 has been treating you well.

I was wondering if you had availability for meeting with Chris Gardner and myself. If it would be easier for your schedule we could come to you. The purpose would be to provide an update on Sequence Bio business matters. Specifically to discuss:

- As well, we are excited to share details about our new Chief Scientific Officer.

Do you have availability next week? Please let me know some preferred times and we can go from there.

Looking forward to speaking with you.

Regards,
Neala

---

neala quigley
director of community engagement, sequence bio
+1.800.296.3481
sequencebio.com
@sequencebio

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. Emails and files may not be shared with a third party without prior notice and consent. If you have received this email please contact privacy@sequencebio.com.
Thanks Larry. I thought that might be the case. I will let Michael and Gillian know that I will attend and suggest that I will ask Bill to join me.

Thanks kindly,

Judith

Judith Hearn
Assistant Deputy Minister, Business
Department of Tourism, Culture, Industry and Innovation
Government of Newfoundland and Labrador
judithhearn@gov.nl.ca
(709) 729-5160

This company is on our list Judith.

You should attend this meeting if it is ADMs only.

However, I would suggest Bill Woolridge be in attendance as well.

Bill, who has been assigned this account?

Larry

See Michael Harvey’s note below. Have we met with Sequence Bio before? Should Gillian or I join Michael for this meeting?
Larry - is this one of our identified growth firms?

Judith

Sent from my BlackBerry 10 smartphone on the Bell network.

From: Harvey, Michael <michaelharvey@gov.nl.ca>
Sent: Tuesday, January 9, 2018 5:42 PM
To: Hearn, Judith; Skinner, Gillian
Subject: Fwd: Meeting request

Judith / Gillian,

Please see below. Which one of you has carriage of the life sciences sector these days. I have always wanted to ensure both depts were represented when we meet with this company. Which one of you should I invite?

Michael

Michael Harvey
Assistant Deputy Minister (Policy, Planning and Performance Monitoring)
Department of Health and Community Services
Government of Newfoundland and Labrador
Tel: 709 729 3103
Cel: 709 693 8570

Begin forwarded message:

From: Neala Quigley <> Date: January 9, 2018 at 1:44:10 PM NST
To: "Harvey, Michael" <michaelharvey@gov.nl.ca>
Subject: Meeting request

Hi Michael,

I hope you had a wonderful (and relaxing) holiday and that 2018 has been treating you well.

I was wondering if you had availability for meeting with Chris Gardner and myself. If it would be easier for your schedule we could come to you. The purpose would be to provide an update on Sequence Bio business matters. Specifically to discuss:

- As well, we are excited to share details about our new Chief Scientific Officer.

Do you have availability next week? Please let me know some preferred times and we can go from there.

Looking forward to speaking with you.
Regards,
Neala

neala quigley
director of community engagement, sequence bio
+1.800.296.3481 — S.40 (1)
sequencebio.com
@sequencebio
Potential copyright material

If you wish to obtain a copy please contact the ATIPP Office at (709) 729-7072 or atipoffice@gov.nl.ca.
Woolridge, Bill

From: Woolridge, Bill
Sent: Tuesday, March 06, 2018 2:02 PM
To: Hearn, Judith
Cc: Weatherbie, Larry; Humber, Eric; Mundon, Tansy
Subject: RE: Sequence Bio - AIINL

By way of the email trail, TCI has been asked to add a point on what Government has done to support the company.

Since 2015 total non-repayable funds (BDSP) of $24,184 were provided to assist the company with early business development efforts.

A contribution of $250,000 was provided from research programs (RDC) on February 2/17 to assist the company build core technology as the foundation of Sequence Bio's bioinformatics platform and define the process and framework to onboard volunteers in the province into the proposed study. The project is To date we have disbursed $196,000 of the approval.

S. 21(1)(b) of RDC Act

Please let me know if you need additional information.

Bill

-----Original Message-----
From: Hearn, Judith
Sent: Monday, March 05, 2018 11:44 AM
To: Woolridge, Bill
Subject: FW: Sequence Bio - AIINL
Importance: High

Hi Bill,

Are you able to help with this request?

Judith

Judith Hearn
Assistant Deputy Minister, Business
Department of Tourism, Culture, Industry and Innovation Government of Newfoundland and Labrador
judithhearn@gov.nl.ca
(709) 729-5160

-----Original Message-----
From: Mundon, Tansy
Sent: Monday, March 05, 2018 11:18 AM
To: Skinner, Gillian; Hearn, Judith
Cc: Humber, Eric
Hi Eric, we are working on key messages for this issue. We thought it may be appropriate to add a point on what Government has done to support the company. Would you be able to provide? I understand Tina and Tansy have spoken on this.

Emily

Hello Tina/Tansy,

There is an article this morning on allNL.com related to Sequence Bio. I've attached screen shots of the story for you.

Scott
Potential copyright material

If you wish to obtain a copy please contact the ATIPP Office at (709) 729-7072 or atipoffice@gov.nl.ca.
Hi Folks,

I am happy to attend this meeting with Michael.

Michael, had you thought we would keep this at the ADM level? If you are having other staff join the meeting, I would like to bring Bill Woolridge with me and perhaps someone from Gillian's shop on the Life Science side – let me know.

Thanks

Judith

Judith Hearn
Assistant Deputy Minister, Business
Department of Tourism, Culture, Industry and Innovation
Government of Newfoundland and Labrador
judith.hearn@gov.nl.ca
(709) 729-5160

From: Harvey, Michael
Sent: Tuesday, January 09, 2018 5:42 PM
To: Hearn, Judith; Skinner, Gillian
Subject: Fwd: Meeting request

McAfee Web Control Warning
This e-mail message contains potentially unsafe links to these sites:

Judith / Gillian,

Please see below. Which one of you has carriage of the life sciences sector these days. I have always wanted to ensure both depts were represented when we meet with this company. Which one of you should I invite?

Michael

Michael Harvey
Assistant Deputy Minister (Policy, Planning and Performance Monitoring)
Department of Health and Community Services
Government of Newfoundland and Labrador
Tel: 709 729 3103
Cel: 709 693 8570
Begin forwarded message:

From: Neala Quigley <neala.quigley@sequencebio.com>
Date: January 9, 2018 at 1:44:10 PM NST
To: "Harvey, Michael" <michaelharvey@gov.nl.ca>
Subject: Meeting request

Hi Michael,

I hope you had a wonderful (and relaxing) holiday and that 2018 has been treating you well.

I was wondering if you had availability for meeting with Chris Gardner and myself. If it would be easier for your schedule we could come to you. The purpose would be to provide an update on Sequence Bio business matters. Specifically to discuss:

- As well, we are excited to share details about our new Chief Scientific Officer.

Do you have availability next week? Please let me know some preferred times and we can go from there.

Looking forward to speaking with you.

Regards,
Neala
Generally we have included officials in these meetings. Kirk has been a constant. How about I just include you and Gillian on the invite and we will take it from there with officials.

Michael

Michael Harvey
Assistant Deputy Minister (Policy, Planning and Performance Monitoring)
Department of Health and Community Services
Government of Newfoundland and Labrador
Tel: 709 729 3103
Cel: 709 693 8570

On Jan 10, 2018, at 9:32 AM, Hearn, Judith <JudithHearn@gov.nl.ca> wrote:

Hi Folks,

I am happy to attend this meeting with Michael.

Michael, had you thought we would keep this at the ADM level? If you are having other staff join the meeting, I would like to bring Bill Woolridge with me and perhaps someone from Gillian’s shop on the Life Science side – let me know.

Thanks

Judith

Judith Hearn
Assistant Deputy Minister, Business
Department of Tourism, Culture, Industry and Innovation
Government of Newfoundland and Labrador
judithhearn@gov.nl.ca
(709) 729-5160

From: Harvey, Michael
Sent: Tuesday, January 09, 2018 5:42 PM
To: Hearn, Judith; Skinner, Gillian
Subject: Fwd: Meeting request

McAfee Web Control Warning
Judith / Gillian,

Please see below. Which one of you has carriage of the life sciences sector these days. I have always wanted to ensure both depts were represented when we meet with this company. Which one of you should I invite?

Michael

Michael Harvey
Assistant Deputy Minister (Policy, Planning and Performance Monitoring)
Department of Health and Community Services
Government of Newfoundland and Labrador
Tel: 709 729 3103
Cel: 709 693 8570

Begin forwarded message:

From: Neala Quigley <[redacted]>
Date: January 9, 2018 at 1:44:10 PM NST
To: "Harvey, Michael" <michaelharvey@gov.nl.ca>
Subject: Meeting request

Hi Michael,

I hope you had a wonderful (and relaxing) holiday and that 2018 has been treating you well.

I was wondering if you had availability for meeting with Chris Gardner and myself. If it would be easier for your schedule we could come to you. The purpose would be to provide an update on Sequence Bio business matters. Specifically to discuss:

- As well, we are excited to share details about our new Chief Scientific Officer.

Do you have availability next week? Please let me know some preferred times and we can go from there.

Looking forward to speaking with you.

Regards,
neala quigley
director of community engagement, sequence bio
+1.800.296.3481
sequencebio.com
@sequencebio

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom addressed. Emails and files may not be shared with a third party without prior notice and consent. If you have received an email in error please contact privacy@sequencebio.com.
Hi Neala,

Very happy to meet with you and Chris. I have copied Judith Hearn and Gillian Skinner on this email and propose that they be included in this meeting. As you know, I feel it is helpful that both HCS and TCII be represented in meetings with SB and Judith and Gillian were both appointed just before the holidays as ADMs in that department. I’m sure that they would appreciate a good briefing on what you are up to.

Finally, I have copied Connie Fry who can help set up the meeting. Just to throw some times out there, 11 am next Wednesday, 9:30 next Thursday or 3:30 next Friday would work for me, though I can’t speak for Gillian and Judith.

Thanks,
Michael

Michael Harvey
3103

Hi Michael,

I hope you had a wonderful (and relaxing) holiday and that 2018 has been treating you well.

I was wondering if you had availability for meeting with Chris Gardner and myself. If it would be easier for your schedule we could come to you. The purpose would be to provide an update on Sequence Bio business matters. Specifically to discuss:

- As well, we are excited to share details about our new Chief Scientific Officer.

Do you have availability next week? Please let me know some preferred times and we can go from there.

Looking forward to speaking with you.

Regards,
Neala
neala quigley
director of community engagement, sequence bio
+1.600.296.3481 S.40 (1)
sequencebio.com
@sequencebio

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. Emails and files may not be shared with a third party without prior notice and consent. If you have received this email in error please contact privacy@sequencebio.com
From: Skinner, Gillian
Sent: Wednesday, January 10, 2018 1:40 PM
To: Harvey, Michael; Hearn, Judith
Subject: RE: Meeting request

Hi
Sorry for delay. To close loop, you are correct on the life sciences sector work and Kirk is well up to speed on the various initiatives. To Judith’s point, beneficial for us both and I’ve mentioned this to Kirk Youden, given his involvement in the sector and with the company. Kirk and/or I will attend. We will respond to the other email re availability. Thanks

From: Harvey, Michael
Sent: Wednesday, January 10, 2018 9:43 AM
To: Hearn, Judith
Cc: Skinner, Gillian
Subject: Re: Meeting request

Generally we have included officials in these meetings. Kirk has been a constant. How about I just include you and Gillian on the invite and we will take it from there with officials.

Michael

Michael Harvey
Assistant Deputy Minister (Policy, Planning and Performance Monitoring)
Department of Health and Community Services
Government of Newfoundland and Labrador
Tel: 709 729 3103
Cel: 709 693 8570

On Jan 10, 2018, at 9:32 AM, Hearn, Judith <JudithHearn@gov.nl.ca> wrote:

Hi Folks,

I am happy to attend this meeting with Michael.

Michael, had you thought we would keep this at the ADM level? If you are having other staff join the meeting, I would like to bring Bill Woolridge with me and perhaps someone from Gillian’s shop on the Life Science side – let me know.

Thanks

Judith

Judith Hearn
Assistant Deputy Minister, Business
Department of Tourism, Culture, Industry and Innovation
Government of Newfoundland and Labrador
judithhearn@gov.nl.ca
From: Harvey, Michael  
Sent: Tuesday, January 09, 2018 5:42 PM  
To: Hearn, Judith; Skinner, Gillian  
Subject: Fwd: Meeting request

McAfee Web Control Warning

This e-mail message contains potentially unsafe links to these sites:

Judith / Gillian,

Please see below. Which one of you has carriage of the life sciences sector these days. I have always wanted to ensure both depts were represented when we meet with this company. Which one of you should I invite?

Michael

Michael Harvey  
Assistant Deputy Minister (Policy, Planning and Performance Monitoring)  
Department of Health and Community Services  
Government of Newfoundland and Labrador  
Tel: 709 729 3103  
Cel: 709 693 8570

Begin forwarded message:

From: Neala Quigley <[redacted]>  
Date: January 9, 2018 at 1:44:10 PM NST  
To: "Harvey, Michael" <michaelharvey@gov.nl.ca>  
Subject: Meeting request

Hi Michael,

I hope you had a wonderful (and relaxing) holiday and that 2018 has been treating you well.

I was wondering if you had availability for meeting with Chris Gardner and myself. If it would be easier for your schedule we could come to you. The purpose would be to provide an update on Sequence Bio business matters. Specifically to discuss:

• As well, we are excited to share details about our new Chief Scientific Officer.

Do you have availability next week? Please let me know some preferred times and we can go from there.

Looking forward to speaking with you.

Regards,
Neala

neala quigley
director of community engagement, sequence bio
+1.800.296.3481
sequencebio.com
@sequencebio

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to which addressed. Emails and files may not be shared with a third party without prior notice and consent. If you have received error please contact privacy@sequencebio.com
Hi Neala,

Looking forward to hearing the Sequence Bio update!

With respect to Michael’s suggested meeting times - 9:30am next Thursday, January 18 will work for me – otherwise sometime on Monday, January 22 could also work if there was a time that day that might work for others? I am expecting to be out of town on Friday, January 19 so unable to make that date.

Thanks kindly,

Judy

Judith Hearn
Assistant Deputy Minister, Business
Department of Tourism, Culture, Industry and Innovation
Government of Newfoundland and Labrador
judithhearn@gov.nl.ca
(709) 729-5160

Hi Neala,

Very happy to meet with you and Chris. I have copied Judith Hearn and Gillian Skinner on this email and propose that they be included in this meeting. As you know, I feel it is helpful that both HCS and TCII be represented in meetings with SB and Judith and Gillian were both appointed just before the holidays as ADMs in that department. I’m sure that they would appreciate a good briefing on what you are up to.

Finally, I have copied Connie Fry who can help set up the meeting. Just to throw some times out there, 11 am next Wednesday, 9:30 next Thursday or 3:30 next Friday would work for me, though I can’t speak for Gillian and Judith.

Thanks,

Michael

Michael Harvey
3103
Hi Michael,

I hope you had a wonderful (and relaxing) holiday and that 2018 has been treating you well.

I was wondering if you had availability for meeting with Chris Gardner and myself. If it would be easier for your schedule we could come to you. The purpose would be to provide an update on Sequence Bio business matters. Specifically to discuss:

- As well, we are excited to share details about our new Chief Scientific Officer.

Do you have availability next week? Please let me know some preferred times and we can go from there.

Looking forward to speaking with you.

Regards,
Neala

---

neala quigley
director of community engagement, sequence bio
+1.800.296.3481
sequencebio.com
@sequencebio

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. Emails and files may not be shared with a third party without prior notice and consent. If you have received this email in error please contact privacy@sequencebio.com
Good Afternoon,

Following up to thank you all for meeting with myself and Chris this week. We appreciate having the opportunity to speak with you.

As mentioned, we have appointed Dr. Michael Phillips as Chief Scientific Officer at Sequence Bio. I have attached a copy of the press release for your review.

Have a great weekend.

Regards,

Neala

neala.quigley@sequencebio.com
+1.600.296.3485
@sequencebio

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. Emails and files may not be shared with a third party without prior notice and consent. If you have received this email in error please contact privacy@sequencebio.com.
Potential copyright material

If you wish to obtain a copy please contact the ATIPP Office at (709) 729-7072 or atippoffice@gov.nl.ca.
Is this information easily available? Total investment in Sequence Bio?

----- Original Message -----  
From: Timmins, Emily  
Sent: Monday, March 5, 2018 11:15 AM  
To: Humber, Eric <EricHumber@gov.nl.ca>  
Cc: Williams, Tina (HCS) <TinaWilliams@gov.nl.ca>; Munden, Tansy <TansyMunden@gov.nl.ca>  
Subject: FW: Sequence Bio - AllNL  

Hi Eric, we are working on key messages for this issue.  
We thought it may be appropriate to add a point on what Government has done to support the company. Would you be able to provide? I understand Tina and Tansy have spoken on this.  
Emily

----- Original Message -----  
From: Barfoot, Scott  
Sent: Monday, March 5, 2018 7:57 AM  
To: Williams, Tina (HCS); Munden, Tansy  
Cc: Cannizzaro, Michelle; Card, Jason; Foote, Carla; Joyce, Luke  
Subject: Sequence Bio - AllNL  

Hello Tina/Tansy,  

There is an article this morning on alnl.com related to Sequence Bio.  
I've attached screen shots of the story for you.  
Scott

----- Original Message -----  
From: Scott Barfoot <mailto:Scott.Barfoot@gov.nl.ca>  
Sent: Monday, March 5, 2018 7:53 AM  
To: Barfoot, Scott  
Subject: A
---Original Message---
From: Barfoot, Scott
Sent: Monday, March 5, 2018 7:53 AM
To: Williams, Tina (HCS) <TinaWilliams@gov.nl.ca>; Mundon, Tansy <TansyMundon@gov.nl.ca>
Cc: Cannizzaro, Michelle <MichelleCannizzaro@gov.nl.ca>; Card, Jason <JasonCard@gov.nl.ca>; Foote, Carla <CarlaFoote@gov.nl.ca>; Joyce, Luke <LukeJoyce@gov.nl.ca>
Subject: Sequence Bio - AllNL

Hello Tina/Tansy,

There is an article this morning on allNL.com related to Sequence Bio. I've attached screen shots of the story for you.
Scott

---Original Message---
From: Scott Barfoot (mailto:Scott.Barfoot@gov.nl.ca) [S.40 (1)]
Sent: Monday, March 5, 2018 7:53 AM
To: Barfoot, Scott
Subject: A
Hearn, Judith

Fyi. Ted

Sent from my BlackBerry 10 smartphone on the Bell network.

From: Dave Phillips <dphillips@sequencebio.com>
Sent: Tuesday, March 6, 2018 7:18 PM
To: Premier of NL
Cc: Chris Gardner; Mark Dobbin; Minister, HCS; TCII Minister; Lomond, Ted; Harvey, Michael; Abbott, John
Subject: House of Assembly Proceedings - March 5, 2018

Dear Premier Ball,

On behalf of our CEO, Chris Gardner, please see attached for a letter regarding the House of Assembly proceedings dated March 5, 2018.

Best regards,

David Phillips
Director of Finance and Admin, Sequence Bio
+1 800 296 3481
sequencebio.com
davidphillips@sequencebio.com

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. Emails and files may not be shared with a third party without prior notice and consent. If you have received this email in error please contact privacy@sequencebio.com.
The Honourable Dwight Ball, Premier of Newfoundland and Labrador
The Office of the Premier
Confederation Building, East Block
P.O. Box 8700
St. John's, NL
A1B 4J6

March 6, 2018

Dear Premier Ball,

I am writing in regards to incorrect statements made during House of Assembly proceedings on March 5, 2018, regarding our company, Sequence Bio. In particular, the following comments should be corrected:

Comment #1:

- **PREMIER BALL**: “What the Member opposite doesn’t know is that it was actually the company [Sequence Bio] themselves that voluntarily withdrew their application.”

Correction: Sequence Bio's Newfoundland and Labrador Genome Pilot Project (NLGP) was submitted to the Health Research Ethics Board's Clinical Trials subcommittee (HREB-CT) on August 30, 2017 - 188 days ago. We have not received meaningful feedback on this application for 88 days, nor have we been permitted to meet with the HREB-CT, despite requesting to do so at least six times. We have not withdrawn this application.

Comment #2:

- **MR. HAGGIE**: “[The HREBs] undertake to begin consideration of applications within 30 Days.”

Correction: Section 9.4 of the HREA Act compels the regulatory body to either (a) approve the application; (b) approve the application subject to the changes the board or other body may require; or (c) refuse to approve the application within 30 days.

The people and province of Newfoundland and Labrador should expect our regulatory bodies to fulfill the duties entrusted upon them in a manner consistent with other Canadian jurisdictions. Regardless of any interpretation, we have been awaiting a decision for over six times the Canadian average duration.

Furthermore, Section 8 of the HREA Act states, “The authority may approve a research ethics body if: (a) it is a not-for-profit body; and (b) it is established in conformity with the principles respecting the appointment of members to a research ethics board contained in the tri-council
There are a number of non-profit research ethics bodies across the country that meet these requirements. If the HREA is unable to fulfil its duty, it should be compelled to approve an additional regulatory body that can help expedite the research application review process, as the HREA Act outlines above. This solution would not come at any cost to the province, and it would drastically improve the process of facilitating timely review and approval of ethical research in Newfoundland and Labrador.

Ethical research backed by scientific excellence is the backbone of Sequence Bio. We strongly support an independent, efficient and ethical review process - it is critical to protecting the interests of the people of this province. However, it is clear that the HREA is disadvantaging all Newfoundland and Labradorian researchers and patients because it can not properly govern itself. The HREA is not capable of ensuring timely reviews of potentially groundbreaking human research. This is bad for researchers, patients and business. It’s bad for Newfoundland and Labrador.

Unfortunately, the message being sent right now is: Newfoundland and Labrador is closed to the lucrative biotech sector.

We look forward to having further conversations with you and working together to ensure that we can remedy these issues - not just for Sequence Bio, but for the betterment of the biotechnology industry and innovation in this province.

Regards,

Chris Gardner
President and CEO
Sequence Bio

CC: The Honourable John Haggie, Minister, Dept. of Health & Community Services
Mr. John Abbott, Deputy Minister, Dept. of Health & Community Services
Mr. Michael Harvey, Assistant Deputy Minister, Dept. of Health & Community Services
The Honourable Christopher Mitchelmore, Minister, Dept. of Tourism, Culture, Industry and Innovation
Mr. Ted Lomond, Deputy Minister, Dept. of Tourism, Culture, Industry & Innovation
Mr. Mark Dobbin, Chair, Board of Directors, Sequence Bio
By way of the email trail, TCII has been asked to add a point on what Government has done to support the company.

Since 2015 total non-repayable funds (BDSP) of $24,184 were provided to assist the company with early business development efforts.

A contribution of $250,000 was provided from research programs (RDC) on February 2/17 to assist the company build core technology as the foundation of Sequence Bio's bioinformatics platform and define the process and framework to onboard volunteers in the province into the proposed study. The project is [Redacted] To date we have disbursed $196,000 of the approval. 

S.21(1)(b) of RDC Act

Please let me know if you need additional information.

Bill

---Original Message---
From: Hearn, Judith
Sent: Monday, March 05, 2018 11:44 AM
To: Woolridge, Bill
Subject: FW: Sequence Bio - AlINL
Importance: High

Hi Bill,

Are you able to help with this request?

Judith

Judith Hearn
Assistant Deputy Minister, Business
Department of Tourism, Culture, Industry and Innovation Government of Newfoundland and Labrador
judithhearn@gov.nl.ca
(709) 729-5160

---Original Message---
From: Mundon, Tansy
Sent: Monday, March 05, 2018 11:18 AM
To: Skinner, Gillian; Hearn, Judith
Cc: Humber, Eric
Is this information easily available? Total investment in Sequence Bio?

-----Original Message-----
From: Timmins, Emily
Sent: Monday, March 5, 2018 11:15 AM
To: Humber, Eric <EricHumber@gov.nl.ca>
Cc: Williams, Tina (HCS) <TinaWilliams@gov.nl.ca>; Mundon, Tansy <TansyMundon@gov.nl.ca>
Subject: FW: Sequence Bio - AINL

Hi Eric, we are working on key messages for this issue.
We thought it may be appropriate to add a point on what Government has done to support the company. Would you be able to provide? I understand Tina and Tansy have spoken on this.
Emily

-----Original Message-----
From: Barfoot, Scott
Sent: Monday, March 05, 2018 7:57 AM
To: Williams, Tina (HCS); Mundon, Tansy
Cc: Cannizzaro, Michelle; Card, Jason; Foote, Carla; Joyce, Luke
Subject: Sequence Bio - AINL

Hello Tina/Tansy,

There is an article this morning on allNL.com related to Sequence Bio.
I’ve attached screen shots of the story for you.
Scott

-----Original Message-----
From: Scott Barfoot
Sent: Monday, March 05, 2018 7:53 AM
To: Barfoot, Scott
Subject: A
Sequence is a population-genetics company that is utilizing the unique population characteristics of Newfoundland and its excellent Health IT infrastructure to build an unparalleled population-based resource containing clinical, genomic, epidemiological and family history information.

This information is utilized to create novel insights that can be translated into precision medicine therapeutics and diagnostics.
<table>
<thead>
<tr>
<th>S.39(1)(a)(ii), 39(b), 39(c)(i)</th>
<th>Key Information</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Financial Information</td>
</tr>
</tbody>
</table>
Dear Premier Ball,

On behalf of our CEO, Chris Gardner, please see attached for a letter regarding the House of Assembly proceedings dated March 5, 2018.

Best regards,

David Phillips  CPA, CA
Director of Finance and Admin, Sequence Bio
+1.800.296.3481
sequencebio.com
@sequencebio
The Honourable Dwight Ball, Premier of Newfoundland and Labrador
The Office of the Premier
Confederation Building, East Block
P.O. Box 8700
St. John's, NL
A1B 4J6

March 6, 2018

Dear Premier Ball,

I am writing in regards to incorrect statements made during House of Assembly proceedings on March 5, 2018, regarding our company, Sequence Bio. In particular, the following comments should be corrected:

Comment #1:

- **PREMIER BALL**: “What the Member opposite doesn’t know is that it was actually the company [Sequence Bio] themselves that voluntarily withdrew their application.”

Correction: Sequence Bio’s Newfoundland and Labrador Genome Pilot Project (NLGP) was submitted to the Health Research Ethics Board’s Clinical Trials subcommittee (HREB-CT) on August 30, 2017 - 188 days ago. We have not received meaningful feedback on this application for 88 days, nor have we been permitted to meet with the HREB-CT, despite requesting to do so at least six times. We have not withdrawn this application.

Comment #2:

- **MR. HAGGIE**: “The HREBs undertake to begin consideration of applications within 30 Days.”

Correction: Section 9.4 of The HREA Act compels the regulatory body to either (a) approve the application, (b) approve the application subject to the changes the board or other body may require; or (c) refuse to approve the application within 30 days.

The people and province of Newfoundland and Labrador should expect our regulatory bodies to fulfill the duties entrusted upon them in a manner consistent with other Canadian jurisdictions. Regardless of any interpretation, we have been awaiting a decision for over six times the Canadian average duration.

Furthermore, Section 8 of the HREA Act states, “The authority may approve a research ethics body if: (a) it is a not-for-profit body, and (b) it is established in conformity with the principles respecting the appointment of members to a research ethics board contained in the tri-council..."
policy statement

There are a number of non-profit research ethics bodies across the country that meet these requirements. If the HREA is unable to fulfill its duty, it should be compelled to approve an additional regulatory body that can help expedite the research application review process, as the HREA Act outlines above. This solution would not come at any cost to the province, and it would drastically improve the process of facilitating timely review and approval of ethical research in Newfoundland and Labrador.

Ethical research backed by scientific excellence is the backbone of Sequence Bio. We strongly support an independent, efficient and ethical review process - it is critical to protecting the interests of the people of this province. However, it is clear that the HREA is disadvantaging all Newfoundland and Labradorian researchers and patients because it can not properly govern itself. The HREA is not capable of ensuring timely reviews of potentially groundbreaking human research. This is bad for researchers, patients and business. It’s bad for Newfoundland and Labrador.

Unfortunately, the message being sent right now is: Newfoundland and Labrador is closed to the lucrative biotech sector.

We look forward to having further conversations with you and working together to ensure that we can remedy these issues - not just for Sequence Bio, but for the betterment of the biotechnology industry and innovation in this province.

Regards,

Chris Gardner
President and CEO
Sequence Bio

CC:
The Honourable John Haggie, Minister, Dept. of Health & Community Services
Mr. John Abbott, Deputy Minister, Dept. of Health & Community Services
Mr. Michael Harvey, Assistant Deputy Minister, Dept. of Health & Community Services
The Honourable Christopher Mitchelmore, Minister, Dept. of Tourism, Culture, Industry and Innovation
Mr. Ted Lomond, Deputy Minister, Dept. of Tourism, Culture, Industry & Innovation
Mr. Mark Dobbin, Chair, Board of Directors, Sequence Bio
Gillian,

Thanks for reaching out. I am the contact myself. I can hold then pen and will circulate to Kirk for him to add things to. I will send him something later this week.

Best,
Michael

Michael Harvey
Assistant Deputy Minister (Policy, Planning and Performance Monitoring)
Department of Health and Community Services
Government of Newfoundland and Labrador
Tel: 709 729 3103
Cel: 709 693 8570

On Mar 7, 2018, at 9:18 AM, Skinner, Gillian <GSkinner@gov.nl.ca> wrote:

Hi Michael,

I understand our Ministers are potentially meeting with Mark Dobbin, Chair of Sequence Bio on March 27th. Can we develop a joint meeting note? Kirk Youden would be drafting from TCII. If this works for you, who should he connect with in your dept?

Thanks

Sent from my BlackBerry 10 smartphone on the Bell network.
Brown, Heather

From: Skinner, Gillian  
Sent: Tuesday, March 27, 2018 12:21 PM
To: Brown, Heather
Subject: FW: Meeting request

From: Youden, Kirk  
Sent: Wednesday, January 10, 2018 3:32 PM
To: Skinner, Gillian
Cc: Gilliard, Carol-Ann; Janes, Ed; Sparkes, Lynn A.
Subject: RE: Meeting request

I’m good for these times /or will make myself available.

KIRK YOUDEN 709.729.0595
Development Officer, Innovation Supports Division
Tourism, Culture, Industry & Innovation
Government of Newfoundland and Labrador
P.O. Box 8700
St. John’s, NL Canada
A1B 4J6

From: Skinner, Gillian  
Sent: Wednesday, January 10, 2018 1:41 PM
To: Youden, Kirk
Cc: Gilliard, Carol-Ann; Janes, Ed; Sparkes, Lynn A.
Subject: FW: Meeting request

Hi Kirk

What’s your availability for the times suggested? Thanks

From: Harvey, Michael  
Sent: Wednesday, January 10, 2018 10:23 AM
To: ‘Neala Quigley’
Cc: Hearn, Judith; Skinner, Gillian
Subject: RE: Meeting request

Hi Neala,

Very happy to meet with you and Chris. I have copied Judith Hearn and Gillian Skinner on this email and propose that they be included in this meeting. As you know, I feel it is helpful that both HCS and TCII be represented in meetings with SB and Judith and Gillian were both appointed just before the holidays as ADMs in that department. I’m sure that they would appreciate a good briefing on what you are up to.

Finally, I have copied Connie Fry who can help set up the meeting. Just to throw some times out there, 11 am next Wednesday, 9:30 next Thursday or 3:30 next Friday would work for me, though I can’t speak for Gillian and Judith.
Thanks,
Michael

Michael Harvey
3103

From: Neala Quigley [mailto:...........]
Sent: Tuesday, January 9, 2018 1:44 PM
To: Harvey, Michael <michaelharvey@gov.nl.ca>
Subject: Meeting request

Hi Michael,

I hope you had a wonderful (and relaxing) holiday and that 2018 has been treating you well.

I was wondering if you had availability for meeting with Chris Gardner and myself. If it would be easier for your schedule we could come to you. The purpose would be to provide an update on Sequence Bio business matters. Specifically to discuss:

- As well, we are excited to share details about our new Chief Scientific Officer.

Do you have availability next week? Please let me know some preferred times and we can go from there.

Looking forward to speaking with you.

Regards,
Neala

neala quigley
director of community engagement, sequence bio
+1.800.296.3481
sequencebio.com
@sequencebio
From: Youlden, Kirk
Sent: Thursday, January 18, 2018 9:00 AM
To: Skinner, Gillian; Gilliard, Carol-Ann
Subject: FW: Sequence Bio Update

FYI

KIRK YOUDEN  709.729.0695
Development Officer, Innovation Supports Division
Tourism, Culture, Industry & Innovation
Government of Newfoundland and Labrador
P.O. Box 8700
St. John's, NL Canada
A1B 4J6

From: Lomond, Ted
Sent: Wednesday, January 17, 2018 4:34 PM
To: Youlden, Kirk
Subject: FW: Sequence Bio Update

Ted Lomond
Deputy Minister
Dept. of Tourism, Culture, Industry and Innovation
2nd Floor, West Block, Confederation Building
St. John's, NL A1B 4J6
Telephone: 709-729-4732

From: Chris Gardner
Sent: Wednesday, January 17, 2018 3:35 PM
To: Abbott, John; Lomond, Ted
Cc: Mark Dobbin; Harvey, Michael
Subject: Sequence Bio Update

Hello John and Ted,

I hope your 2018 is off to a great start. I wanted to provide an update to our conversations about Sequence Bio.

Please see a short briefing attached as a pdf.
I'm very happy to report that we've been able to recruit Dr. Michael Phillips from Genomics Medicine Ireland, our biggest competitor, to join us here in NL as our Chief Scientific Officer. This is a significant achievement and is continued validation of the incredible private sector research opportunities this province can develop. Dr. Phillips has raised over $100M to support his various research efforts and helped establish and drive Genomics Medicine Irelands’ research programs.


All the best,

Chris
Mr. John Abbott, Deputy Minister  
Department of Health and Community Services  
P.O. Box 8700  
1st Floor, West Block  
Confederation Building  
St. John's, NL A1B 4J6  

Subject: Sequence Bio Update  

Thank you for your continued support, open channels of communication and hard work for the people of this province. We appreciate working with the province on important issues and as part of my role on the federal Health and Bio-sciences Strategy Table. I have also had the opportunity to work with your colleagues on a federal level, including the Deputy Ministers of Health Canada and Innovation, Science and Economic Development. By facilitating open communications like this, we have the opportunity to make a measurable difference.  

As we start 2018, I wanted to provide an update on the status of the NL Genome Pilot Project, in addition to our experience with the HREA and HREB-CT. As you are aware, we submitted our application to the HREB-CT on August 23, 2017. We were recently informed on December 1, 2017, that the HREB-CT required the services of an external advisor to review our application. This recent development and continued delay in the final review of our application is disappointing, given that we were informed in writing by the HREA Chair on October 3, 2017 that the HREB-CT would have “quorum and subject matter experts” in attendance for their October 19, 2017 meeting. As of this writing, the review process has exceeded 148 days and they took 99 days to seek external expertise.  

Conceding they did not possess the expertise to review our application, the HREB-CT retained the services of an external advisor, and supplied us with this individual’s feedback on December 8, 2017. No specific scientific, ethical or technical merits of the protocol were raised by the advisor in reference to specific pieces of TCPS2 or other relevant legislation. All commentary raised by reviewer is addressable, which is consistent with prior comments received from the HREB-CT to date. Once addressed, we believe there is no grounds, absent of bias or incompetence, why the HREB-CT could not render a decision on this important research project. To that end, we are encouraged that some progress has been made.  

However, in order for our feedback to be addressed by the HREB-CT at their December 16, 2017 meeting, we were required to respond to the advisor’s comments within two business days. This was not feasible given the nature of the advisor’s feedback. For example, the advisor opined that Sequence Bio needed to add more people to its team. This demonstrated a lack of understanding about the expertise of our team and the nature of research we are performing - again which could be mitigated if they HREB-CT, HREA or the advisor were to accept one of our numerous meeting requests. Nonetheless, as a result of this feedback, we added new team members ahead of
schedule. Most notably, Sequence Bio is proud to announce the recruitment of Dr. Michael Phillips as Chief Scientific Officer. Dr. Phillips' extensive population genomics research and drug development background will bring significant experience to this province and present not only opportunities for Sequence Bio to be successful but to benefit both the NL biotech industry and support academic research. You can read more about Dr. Phillips' background at sequencebio.com.

This hiring comes at a great cost to Sequence Bio, and until the NL Genome Pilot Project is approved, he will have limited work to perform. We hope this significant commitment is recognized by the HREB-CT, and demonstrates to all parties our continued collaborative effort.

We continue to seek a positive and collaborative relationship with our regulator; however, our meeting requests continue to be denied by the HREB-CT and the HREA. We were encouraged by the HREA Chair's recent letter which stated "I would like seek a way forward with Sequence Bio that builds a collaborative relationship of trust and mutual respect ensuring independence from the ethic review process." However, when we subsequently requested a meeting with the HREA we were denied and told from their lawyer that "they don't really see the point of having a meeting." Simply put, we are making sincere efforts to work together but their behavior seems to consist of empty platitudes that are contrary to the underlying principles of transparency and ethical behavior.

We are confident that much of the delay, misinformation and misunderstanding exhibited by the HREB-CT and ad hoc advisor regarding the nature / goals of this project, as well as the expertise, composition and functioning of our team could have been avoided (and still mitigated) by engaging in an in-person dialog. As we are reminded in our most recent conversation with world-renowned bioethicist Dr. Bartha Knoppers, the HREB-CT's ongoing refusal to meet and discuss this protocol is contrary to the practice of every other IRB and as outlined in TCPS2 (Section 6.13 of TCPS2 states that "The REB shall accommodate reasonable requests from researchers to participate in discussions about their proposals."

As the Chair of the HREA is appointed by the Minister of Health and Community Services, we feel that you should be aware of this inappropriate behavior. Furthermore, we have uncovered instances of bias and defamation through ATIPPA requests. The Chair has also indicated that "the HREA and HREB are cognizant of the time considerations and the legislation but they are also operating within reality; all parties are working to the extent of their efforts." Sequence Bio considers the law to be the reality in which we all must operate. The Chair's inability to meet this standard falls short of her duties to ensure proper governance of this Government body. The HREA and its Chair continue to fail to provide any assurances or transparency that would ensure the application review process is free of bias and follows legislation.

We look forward to working with our regulator and the Government to help provide input when the HREA Act is put up for review, which we again recommend as it has been over 10 years since its introduction. If the province can help find a way for our only REB to act in accordance with legislation and other functioning jurisdictions, we believe that we can build new and important industry and ensure better access to improved care for Newfoundlanders and Labradorians.
Thank you again for your support in 2017, and we look forward to a collaborative 2018. We will be contacting the Department of Health and Community Services regarding a support letter which would greatly assist Sequence Bio in the new year.

Sincerely,

Chris Gardner
President & CEO
Sequence Bio

CC:
Mr. Michael Harvey, Assistant Deputy Minister, Dept. of Health & Community Services
Mr. Mark Dobbin, Chair, Board of Directors, Sequence Bio
Brown, Heather

From: Skinner, Gillian
Sent: Tuesday, March 27, 2018 12:29 PM
To: Brown, Heather
Subject: FW: Sequence Bio Update
Attachments: Briefing - Genomics Medicine Ireland 13092017.pdf; Briefing - The NLGP 19092017.pdf; Briefing Business Model 13092017.pdf; Briefing Data Storage 18092017.pdf; Briefing Sequencing 18092017.pdf

From: Youden, Kirk
Sent: Wednesday, January 17, 2018 4:04 PM
To: Skinner, Gillian; Gilliard, Carol-Ann
Subject: FW: Sequence Bio Update

While a little dated from the Fall, most of these briefing materials still relevant. Provides some background.

KIRK YOUDEN 709.729.0595
Development Officer, Innovation Supports Division
Tourism, Culture, Industry & Innovation
Government of Newfoundland and Labrador
P.O. Box 8700
St. John's, NL Canada
A1B 4J6

From: Neala Quigley [mailto:...]
Sent: Wednesday, September 20, 2017 10:22 AM
To: Harvey, Michael; Keiley, Marc; Youden, Kirk
Cc: Dan Brake
Subject: Sequence Bio Update

Good Morning,

I hope you are well.

I wanted to provide an update on the action items that were discussed at our July 11th meeting and the status of each item.

I have listed the key action items that were agreed upon by all parties. See below:

Department of Health and Community Services (DOHCS):

Tourism, Culture, Industry and Innovation (TCII):
Sequence Bio:
1. Supply TRA/PIA executive summaries from CGI
   - Emailed on July 13, 2017

2. Prepare updated Sequence Bio briefings on overall business areas for Tourism, Culture, Industry and Innovation (TCII) and Department of Health and Community Services (DOHCS):
   - List of briefings include:
     - Data
     - Business Model
     - Sequencing
     - nl Genome Project
     - Genomics Medicine Ireland

3. Supply information on Genomics Medicine Ireland (GMI)
   - Attached briefing on publically available information on GMI. One of the areas of interest discussed during our July meeting was the comparison of Sequence Bio and GMI’s data storage. Although GMI and Sequence Bio have similar initiatives we differ in data storage.

4. Have NLCHI evaluate Sequence Bio Security and Privacy program
   - NLCHI technology team are in the process of an evaluation of Sequence Bio’s technology and Security Platform and will provide a written report. NLCHI’s estimated time of completion: September 22, 2017

5. Meet with TPMI to discuss future possibilities of working together
   - Met with Lynn Taylor and Catherine Street on July 17th, 2017. We asked to be part of a community, together with TPMI, to make the best use of the data we hope to generate from our research (subject to HREB approval). This collaboration with TPMI would hope to help improve clinical best practices. Catherine Street thought it would be best to have conversations with Dr. Proton Rahman and Dr. Terri-Lynn Young. We communicated that we have requested meetings with Drs. Rahman and Young however they have been difficult to obtain. We also mentioned that we would be interested in working with TPMI in the future.

At this time, I would also like to offer an in-person briefing on the NL Genome Pilot Project (NLGP) Research Protocol and accompanying application with government stakeholders.

Please feel free to reach out at any time.

Many thanks,
Neala

neala quigley
director of community engagement, sequence bio
+1 800.296.3461
sequencebio.com
@sequencebio
Potential copyright material

If you wish to obtain a copy please contact the ATIPP Office at (709) 729-7072 or atippoffice@gov.nl.ca.
Gillian,

Thanks for reaching out. I am the contact myself. I can hold then pen and will circulate to Kirk for him to add things to. I will send him something later this week.

Best,
Michael

Michael Harvey
Assistant Deputy Minister (Policy, Planning and Performance Monitoring)
Department of Health and Community Services
Government of Newfoundland and Labrador
Tel: 709 729 3103
Cel: 709 693 8570

On Mar 7, 2018, at 9:18 AM, Skinner, Gillian <GSkinner@gov.nl.ca> wrote:

Hi Michael,

I understand our Ministers are potentially meeting with Mark Dobbin, Chair of Sequence Bio on March 27th. Can we develop a joint meeting note? Kirk Youden would be drafting from TCII. If this works for you, who should he connect with in your dept?

Thanks

Sent from my BlackBerry 10 smartphone on the Bell network.
Potential copyright material

If you wish to obtain a copy please contact the ATIPP Office at (709) 729-7072 or atippoffice@gov.nl.ca.
1. Quality and Scientific Approach

A. Comment on current technology in this sector/area. How is this project expected to address a specific technology gap?

B. Is this a new, unique and/or innovative product, service or facility? If not, comment on the potential for R&D and innovation as a result of this project.

<table>
<thead>
<tr>
<th>Ranking: Quality and Scientific Approach</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very Weak</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Weak</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Strong</td>
<td>3</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very Strong</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2. Stage of Development and Project Team

A. What is the present stage of development? (Focus on applicant R&D history, alignment with corporate goals, current business or future opportunities/development priorities). **NO RATING REQUIRED**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>

B. Does the project team have technical expertise to complete the project? (Focus on the key individuals/collaborators involved, their roles and responsibilities, qualifications, experience and whether they have relevance to the project). **NO RATING REQUIRED**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>
3. Project Plan

A. Is the proposed project plan and schedule credible? (Focus on the proposed research plan, objectives, identifiable milestones, and measurable outcomes. Are the outcomes realistic and achievable within the proposed schedule?)

<table>
<thead>
<tr>
<th>Ranking: Project Plan</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very Strong</td>
<td>4</td>
</tr>
<tr>
<td>Strong</td>
<td>3</td>
</tr>
<tr>
<td>Weak</td>
<td>2</td>
</tr>
<tr>
<td>Very Weak</td>
<td>1</td>
</tr>
</tbody>
</table>

4. Economic Potential

A. Is the R&D that will be supported relevant to the industry and/or the Newfoundland and Labrador economy? NO RATING REQUIRED
5. Commercial Potential

A. Are there any serious barriers to commercialization for this project? (Focus on identified technical or market problem/need, line-of-sight to market, applicant commercialization history, etc.).

<table>
<thead>
<tr>
<th>Ranking: Commercial Potential [X]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very Strong</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>Strong</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>Weak</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>Very Weak</td>
</tr>
<tr>
<td>1</td>
</tr>
</tbody>
</table>

6. General Comments

A. Any other specific comments, concerns or issues related to the project or the project budget?
Hi Andrew,

S.21(1)(b) of RDC Act

Cheers,

C

Christopher Brown

Industrial Technology Advisor, Atlantic & Nunavut
Industrial Research Assistance Program
National Research Council Canada | Government of Canada
tel: 709.772.8506 fax: 709.772.5067

Conseiller en technologie industrielle, Atlantique et Nunavut
Programme d'aide à la recherche industrielle
Conseil national de recherches Canada | Gouvernement du Canada
tél: 709.772.8506 télécopieur: 709.772.5067

Please do not transmit any confidential information by email or email attachment.
Veuillez ne pas transmettre par courriel et par pièces jointes toute information jugée confidentielle.
February 17, 2017

Mr. Chris Gardner  
Chief Operating Officer  
Sequence Bioinformatics Inc.  
30 Harvey Road, Suite 2  
St. John’s, NL  A1C 3G1

Dear Mr. Gardner:

Re: Technical Pilot Project (5405-2146-101)

The application for this project has been assessed in relation to the Research & Development Corporation’s R&D Proof of Concept program eligibility criteria. The R&D Proof of Concept Program provides businesses with a mechanism to mitigate the technical and financial risk of research and development.

Please be advised that the application for this project has been deemed eligible under the R&D Proof of Concept program criteria. This project has been approved for the amount of $250,000.00, subject to the negotiation of an acceptable final statement of work and contract between Sequence Bioinformatics Inc. and the Research & Development Corporation. Sequence Bioinformatics Inc. has 25 days from the date of this offer in which to complete the project contract with the Research & Development Corporation.

If you have any questions or require additional information, please contact Anne Bailey at 709-758-0994 or annebailey@rdc.org.

Sincerely,

[Signature]

Levi May  
Chief Financial Officer
Hi Courtney,

Can you put together an SOW for Sequence Bio 5405.2146.101. [redacted] and Work Plan documents will be the best source of info.

Thanks,

Andrew Simmons
Account Manager

Research & Development Corporation
68 Portugal Cove Road
St. John's, NL
A1B 2L9
Tel 1.709.330.2622 Fax 1.709.758.0927

www.rdc.org
Hi Courtney,

SBI's updated SOW is attached. Can you update manifest and finish putting together the contract.

Thanks!

Andrew

Hi Andrew,

I spotted a couple of things in the contract and statement of work which we should change before we go ahead with final signatures.

CONTRACT  
S.21(1)(b) of RDC Act

STATEMENT OF WORK  
S.21(1)(b) of RDC Act

Also attached is a copy of the insurance coverage you requested and a public project statement.

Drop me a line if you want to discuss any of the above.

Have a great weekend.

Dan
On Tue, Feb 21, 2017 at 10:47 AM, Simmons, Andrew E <Andrewesimmons@rdc.org> wrote:

Hi Dan,

SOW and draft contract are attached. Can you fill in the indicator of achievements for the milestones and make any other necessary changes to the SOW, especially related to the dates of the milestones.

I’ve put together a description below. I tried to use similar wording to what was in the application. Make any changes you want to this. We’re not too particular on the wording but I never included any partners names so if you want to use any of their names (Genospace etc.) we will need their approval of the description as well.

S.21(1)(b) of RDC Act

Sequence Bioinformatics Inc. (SBI) is a data-driven biotechnology company in Newfoundland and Labrador, Canada. SBI has launched an initiative called the NL 100k Genome Project, which aims to enroll and collect genetic samples from 100,000 NL participants. Through partnership and collaboration the NL 100K Genome Project is designed to improve patient care, enable scientific discovery, accelerate genomic medicine, and stimulate investment and economic growth in the Province of Newfoundland & Labrador.

In support of this initiative, SBI will develop an innovative bioinformatics platform which will be the core technology to support enrollment and integration processes as well as future research and analytics. The goal of this project is to establish the process and platform to support the enrollment of participants in the NL 100k Genome Project.
Let me know if you have any questions.

Thanks,

Andrew

From: Dan Brake [mailto:]  
Sent: Tuesday, February 21, 2017 8:39 AM  
To: Simmons, Andrew E  
Subject: Re: RBI Proof of Concept Application

Hi Andrew,

Hope you had a great weekend.

I will arrange having RDC added as a named insured on our insurance and send you the documentation.

Yes please send along the disclosure statement. Based on the highly regulated environment we are in wording is very important for stakeholder perception.

Send over the SOW and draft contract template when you have them and we will review.

Chris will be signing on this end yes.

Thanks again for all your help.

Dan
On Fri, Feb 17, 2017 at 10:49 AM, Simmons, Andrew E <Andrewesimmons@rdc.org> wrote:

Hi Dan,

RDC has approved SBI’s Proof of Concept Application for $250,000, congratulations. The Letter of Offer is attached.

The next step is to complete the contribution agreement, which includes a Statement of Work. I’ll put together a draft SOW and send for your review.

RDC has an insurance clause in the contract which requires RDC to be added as an additional insured on your commercial general liability insurance. The wording for the clause is below. We need confirmation of this prior to signing the contract, so I would get started on this process.

22. Insurance Coverage

The Company shall obtain and for the term of this Agreement maintain appropriate insurance coverage to the satisfaction of RDC including general liability coverage which shall name RDC as an additional insured.
RDC has an active disclosure policy where we post RDC funded projects on our website, once the contract is finalized. This includes RDC’s contribution, total project costs, and a brief description of the project. I’ll send you a draft of the description, based on the application, for your review.

These are the three main items we need to complete before the contract can be signed. If you’d like, I can send a template version of our contract so your team can review before receiving the signed copy. This may help in identifying any issues or concerns upfront.

I assume Chris will be signing the contract?
Let me know if you have any questions!

Thanks,

Andrew Simmons
Account Manager

Research & Development Corporation
68 Portugal Cove Road
St. John’s, NL
A1B 2L9
Tel 1.709.330.2622 Fax 1.709.758.0927

www.rdc.org

“This email and any attached files are intended for the sole use of the primary and copied addressee(s) and may contain privileged and/or confidential information. Any distribution, use or copying by any means of this information is strictly prohibited. If you received this email in error, please delete it immediately and notify the sender.”
information is strictly prohibited. If you received this email in error, please delete it immediately and notify the sender."
Hiscock, Courtney

From: Simmons, Andrew E
Sent: Wednesday, March 8, 2017 10:51 AM
To: Hiscock, Courtney
Subject: RE: SBI Proof of Concept Application

Thanks Courtney!

From: Hiscock, Courtney
Sent: Wednesday, March 08, 2017 9:40 AM
To: Simmons, Andrew E
Subject: RE: SBI Proof of Concept Application

Hi Andrew,

Manifest, SOW and Contract have all been updated and saved in the electronic folder.

C

From: Simmons, Andrew E
Sent: Wednesday, March 08, 2017 8:46 AM
To: Hiscock, Courtney
Subject: FW: SBI Proof of Concept Application

Hi Courtney,

SBI's updated SOW is attached. Can you update manifest and finish putting together the contract.

Thanks!

Andrew

From: Dan Brake
Sent: Friday, March 03, 2017 4:38 PM
To: Simmons, Andrew E
Subject: Re: SBI Proof of Concept Application

Hi Andrew,

I spotted a couple of things in the contract and statement of work which we should change before we go ahead with final signatures.

**CONTRACT**

S.21(1)(b) of RDC Act
Also attached is a copy of the insurance coverage you requested and a public project statement.

Drop me a line if you want to discuss any of the above.

Have a great weekend.

Dan

---

On Tue, Feb 21, 2017 at 10:47 AM, Simmons, Andrew E <Andrewesimmons@rdc.org> wrote:

Hi Dan,

SOW and draft contract are attached. Can you fill in the indicator of achievements for the milestones and make any other necessary changes to the SOW, especially related to the dates of the milestones.

I've put together a description below. I tried to use similar wording to what was in the application. Make any changes you want to this. We're not too particular on the wording but I never included any partners names so if you want to use any of their names (Genospace, etc.) we will need their approval of the description as well.
Sequence Bioinformatics Inc. (SBI) is a data-driven biotechnology company in Newfoundland and Labrador, Canada. SBI has launched an initiative called the NL 100k Genome Project, which aims to enroll and collect genetic samples from 100,000 NL participants. Through partnership and collaboration the NL 100K Genome Project is designed to improve patient care, enable scientific discovery, accelerate genomic medicine, and stimulate investment and economic growth in the Province of Newfoundland & Labrador.

In support of this initiative, SBI will develop an innovative bioinformatics platform which will be the core technology to support enrollment and integration processes as well as future research and analytics. The goal of this project is to establish the process and platform to support the enrollment of participants in the NL 100k Genome Project.

Let me know if you have any questions.

Thanks,

Andrew

---

From: Dan Brake [mailto:]
Sent: Tuesday, February 21, 2017 8:39 AM
To: Simmons, Andrew E
Subject: Re: SBI Proof of Concept Application

Hi Andrew,

Hope you had a great weekend.

I will arrange having RDC added as a named insured on our insurance and send you the documentation.

Yes please send along the disclosure statement. Based on the highly regulated environment we are in wording is very important for stakeholder perception.
Send over the SOW and draft contract template when you have them and we will review.

Chris will be signing on this end yes.

Thanks again for all your help.

Dan

On Fri, Feb 17, 2017 at 10:49 AM, Simmons, Andrew E <Andrewesimmons@rdc.org> wrote:

Hi Dan,

RDC has approved SBI’s Proof of Concept Application for $250,00, congratulations. The Letter of Offer is attached.

The next step is to complete the contribution agreement, which includes a Statement of Work. I’ll put together a draft SOW and send for your review.
RDC has an insurance clause in the contract which requires RDC to be added as an additional insured on your commercial general liability insurance. The wording for the clause is below. We need confirmation of this prior to signing the contract, so I would get started on this process.

22. Insurance Coverage

The Company shall obtain and for the term of this Agreement maintain appropriate insurance coverage to the satisfaction of RDC including general liability coverage which shall name RDC as an additional insured.

RDC has an active disclosure policy where we post RDC funded projects on our website, once the contract is finalized. This includes RDC’s contribution, total project costs, and a brief description of the project. I’ll send you a draft of the description, based on the application, for your review.

These are the three main items we need to complete before the contract can be signed. If you’d like, I can send a template version of our contract so your team can review before receiving the signed copy. This may help in identifying any issues or concerns upfront.

I assume Chris will be signing the contract?

Let me know if you have any questions!

Thanks,

Andrew Simmons

Account Manager

Research & Development Corporation
68 Portugal Cove Road
St. John’s, NL
A1B 2L9
Tel 1.709.330.2622 Fax 1.709.758.0927

www.rdc.org
"This email and any attached files are intended for the sole use of the primary and copied addressee(s) and may contain privileged and/or confidential information. Any distribution, use or copying by any means of this information is strictly prohibited. If you received this email in error, please delete it immediately and notify the sender."

"This email and any attached files are intended for the sole use of the primary and copied addressee(s) and may contain privileged and/or confidential information. Any distribution, use or copying by any means of this information is strictly prohibited. If you received this email in error, please delete it immediately and notify the sender."
Hi Courtney,

Have a look at the attached. I made some revisions to the spreadsheet. I think for now we should just keep high-level so everyone can simply see who our clients are. I also think we should include the approved amount as well (that will provide everyone with an indication of how much companies have received from us in total). S.21(1)(b) of RDC Act

I did notice that not all my applications or projects were included. I'm not sure if you had some restrictive parameters when you ran your report. So, I'm not sure if any of Aaron's and Andrew's projects are missing as well.

I also think we can give them another report that includes every commercial project we have done, that way they can see everyone we worked with over the years. We should keep these reports separate though.

What do you think?

Thanks,

B 😊

Hi Bill,

Was this what you had in mind?

Courtney
Hi Courtney,

I can take care of these. [Redacted] needs an extension and I already met with [Redacted] so I’ll reach out to these four.

Thanks!!

Andrew

---

Hi Andrew,

Any here that I can send reminders to? Nikki wants to ensure payments are not delayed.
March 17, 2017

Mr. Dan Brake
Director Technology Development
Sequence Bioinformatics Inc.
30 Harvey Road, Suite 2
St. John's, NL A1C 3G1

Dear Mr. Brake:

Re: Technical Pilot Project (S405-2146-101) for Dan Brake

As per the RDC letter of offer dated February 17, 2017, the project titled Technical Pilot Project has been deemed eligible under the R&D Proof of Concept program criteria. This project has been approved for the amount of $250,000.00 and the attached contract and statement of work have been successfully negotiated. Please find enclosed two (2) copies of the contract between Sequence Bioinformatics Inc. and the Research & Development Corporation, signed by RDC. These copies need to be signed by Mr. Gardner. Once signed, please retain one copy for your records and return the other contract to our offices. S.21(1)(b) of RDC Act

Enclosed you will also find the Operating Vendor and Programs Client Setup and Maintenance Form. Please fully complete this form as all program payments will be made via Electronic Funds Transfer. You can drop off the completed form with your signed contract, or send to our offices via:

Mail: Research & Development Corporation
68 Portugal Cove Road
St. John's, NL A1B 2L9

Email: RDCaccounting@rdc.org

Sincerely,

[Signature]
Stacy Butt
Finance Assistant

68 Portugal Cove Road, St. John's, Newfoundland and Labrador A1B 2L9 Canada
Telephone: +1.709.758.0913  Fax: +1.709.758.0927  www.rdc.org
S.21(1)(b) of RDC Act

Please submit completed report to claims@rdc.org.

<table>
<thead>
<tr>
<th>#</th>
<th>Project Milestone</th>
<th>Indicator of Achievement</th>
<th>Date</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>13-May-17</td>
<td>Completed</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>30-Sep-17</td>
<td>In Progress</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td>31-Dec-17</td>
<td>Not Started</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td>31-Dec-17</td>
<td>In Progress</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td>31-Mar-18</td>
<td>In Progress</td>
</tr>
</tbody>
</table>

Add row

S.21(1)(b) of RDC Act

1. Provide an update on all project activities undertaken, significant milestones achieved, and progress made against the project schedule within the designated reporting period, as stated above.
S.21(1)(b) of RDC Act

2. Report and address any unforeseen challenges or significant delays in major activities or project milestones during the reporting period, as stated above.

No unforeseen challenges or delays to report.

3. Has the progress of the project in the reporting period resulted in any material change to the project schedule or scope of work?

3.1 Have the project costs changed, including overall project costs for each year, the cost per activity, or RDC's contribution rate?

3.2 Is the project being carried out at locations other than those listed in the Statement of Work?

3.3 Was there a change in key personnel/collaborators/partners/client corporate ownership?

If yes, to any question in section 3, please provide details:

Confidentiality & Declaration

RDC has the right to protect client confidential information, unless disclosed in agreement with the applicant, or required or authorized by law.

The personal information collected or provided as part of the reporting process will only be used for purposes relating to the operation and evaluation of the relevant funding programs and for statistical reports. All information will be kept confidential and handled as required by the Access to Information and Protection of Privacy Act. Any questions or comments can be directed to Angela Morgan, Access to Information and Protection of Privacy Coordinator, Research & Development Corporation, at 709.758.0913 or angelajmorgan@rdc.org.

Submission of this report confirms that the information provided is accurate and complete, that the primary applicant consents to its submission, and authorizes RDC, if necessary, to contact parties named in the report for further clarification.
From: Dave Phillips [mailto:]
Sent: Monday, May 1, 2017 4:57 PM
To: Coffin, Jordan <jordancoffin@rdc.org>
Subject: Sequence Bio - Advance Claim #1 (May 1 to July 31, 2017)

Hi Jordan,

I hope all is well. As discussed last week, please see attached for our first Advance Claim. If you have any questions or require anything further in relation to the attached please don’t hesitate to let me know - otherwise if all looks good I can forward to the Claims email address for processing.

I’m hoping to start working through our first claim (for November to April) later this week, so as we go through the process I may have a few questions for you for sure.

Thanks very much,
Dave
<table>
<thead>
<tr>
<th>#</th>
<th>Project Milestone</th>
<th>Indicator of Achievement</th>
<th>Date</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>13-May-17</td>
<td>Completed</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>30-Sep-17</td>
<td>In Progress</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td>31-Dec-17</td>
<td>Not Started</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td>31-Dec-17</td>
<td>In Progress</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td>31-mar-18</td>
<td>In Progress</td>
</tr>
</tbody>
</table>

**S.21(1)(b) of RDC Act**

1. Provide an update on all project activities undertaken, significant milestones achieved, and progress made against the project schedule within the designated reporting period, as stated above.
| **Client:** | Sequence BioInformatics Inc. |
| **Project Title:** | Proof of Concept |
| **Contract No:** | POC5405 2146.101 |
| **Reporting Period: (start date)** | 1-Nov-16 |
| **Reporting Period: (end date)** | 30 Apr-17 |
2. Report and address any unforeseen challenges or significant delays in major activities or project milestones during the reporting period, as stated above.

3. Has the progress of the project in the reporting period resulted in any material change to the project schedule or scope of work?

3.1 Have the project costs changed, including overall project costs for each year, the cost per activity, or RDC's contribution rate?

3.2 Is the project being carried out at locations other than those listed in the Statement of Work?

3.3 Was there a change in key personnel/collaborators/partners/client corporate ownership?

If yes, to any question in section 3, please provide details:

Confidentiality & Declaration

RDC has the right to protect client confidential information, unless disclosed in agreement with the applicant, or required or authorized by law.

The personal information collected or provided as part of the reporting process will only be used for purposes relating to the operation and evaluation of the relevant funding programs and for statistical reports. All information will be kept confidential and handled as required by the Access to Information and Protection of Privacy Act. Any questions or comments can be directed to Angela Morgan, Access to Information and Protection of Privacy Coordinator, Research & Development Corporation, at 709.758.0913 or angela.morgan@rdc.org.

Submission of this report confirms that the information provided is accurate and complete, that the primary applicant consents to its submission, and authorizes RDC, if necessary, to contact parties named in the report for further clarification.
Hi Jordan,

I hope all is well. Please refer to the attached for our first claim (Nov 1, 2016 to April 30, 2017) with supporting receipts, as well as an amended Advance for May to July 2017.

If you have any questions in relation to the attached (or require anything further) please don’t hesitate to let me know. Otherwise, if all looks good, moving forward we’ll just submit directly to the claims inbox. Appreciate your help!

Best regards,

Dave

david phillips  CPA, CA

director of finance and admin, sequence bio
+1.800.296.3461  
sequencebio.com
@sequencebio

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. Emails and files may not be copied or forwarded to a third party without prior notice and consent. If you have received this message in error, please contact...
June 21, 2017

David Phillips
Director of Finance
Sequence Bioinformatics
139 Water Street, 2nd Floor
St. John’s, NL A1C 1B2

Dear Mr. Phillips,

Re: Sequence Bioinformatics

RDC is a provincial Crown Corporation responsible for improving Newfoundland and Labrador’s research and development (R&D) performance. The mandate is to strengthen the focus, quantity, quality, and relevance of research and development undertaken in the province and elsewhere for the long-term economic benefit of the province. 

Sequence BioInformatics applied to RDC’s Proof of Concept program to support the project titled “Technical Pilot Project”. This is to confirm that Sequence BioInformatics’ application was successful, with RDC approving $250,000 contribution to the project. The contribution agreement has been finalized and the project is ongoing. RDC’s funding will be used to support the informed consent, platform implementation and data integration activities that will be required to properly handle the workflow and large amounts of data expected to be generated through the 100K Genome Project.

For more detailed information on this project, you can visit http://www.rdc.org/project/technical-pilot-project/.

If you have any questions or require additional information, please contact Anne Bailey at 709-758-0994 or annebailey@rdc.org.

Sincerely,

Paula Clarke
Director, Program Delivery
**S.21(1)(b) of RDC Act**

*Please submit completed report to claims@rdc.org.*

<table>
<thead>
<tr>
<th>#</th>
<th>Project Milestone</th>
<th>Indicator of Achievement</th>
<th>Date</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>13-May-17</td>
<td>Completed</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>30-Nov-17</td>
<td>Completed</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td>31-May-18</td>
<td>Not Started</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td>31-May-18</td>
<td>In Progress</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td>31-May-18</td>
<td>In Progress</td>
</tr>
</tbody>
</table>

1. Provide an update on all project activities undertaken, significant milestones achieved, and progress made against the project schedule within the designated reporting period, as stated above.
2. Report and address any unforeseen challenges or significant delays in major activities or project milestones during the reporting period, as state above.
### 3. Has the progress of the project in the reporting period resulted in any material change to the project schedule or scope of work?

#### 3.1 Have the project costs changed, including overall project costs for each year, the cost per activity, or RDC's contribution rate?

#### 3.2 Is the project being carried out at locations other than those listed in the Statement of Work?

#### 3.3 Was there a change in key personnel/collaborators/partners/client corporate ownership?

*If yes, to any question in section 3, please provide details:*
<table>
<thead>
<tr>
<th>Client:</th>
<th>Sequence Bioinformatics Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title:</td>
<td>Proof of Concept</td>
</tr>
<tr>
<td>Contract No:</td>
<td>POCS405 2146 101</td>
</tr>
<tr>
<td>Reporting Period:</td>
<td></td>
</tr>
<tr>
<td>(start date)</td>
<td>1-Aug-17</td>
</tr>
<tr>
<td>(end date)</td>
<td>30-Nov-17</td>
</tr>
</tbody>
</table>

**COMMERCIAL PROGRESS REPORT - FORM E**

S.21(1)(b) of RDC Act

**Confidentiality & Declaration**
Mr. Chris Gardner  
Chief Operating Officer  
Sequence Bioinformatics Inc.  
30 Harvey Road, Suite 2  
St. John's, NL A1C 3G1

Dear Mr. Gardner:

Re: Technical Pilot Project (S405-2146-101) for Dan Brake

In response to the contract change for this project that was requested on July 7, 2017, I am pleased to approve this change regarding the R&D Proof of Concept award for Technical Pilot Project.

The following is a summary of the approved contract change:

* [Redacted]

S.21(1)(b) of RDC Act

It is agreed that this approval does not affect the project scope or cost associated with this project.

If you have any questions or require additional information, please contact Anne Bailey at 709-758-0994 or annebailey@rdc.org.

Sincerely,

Ted Lomond  
Chief Executive Officer  

Aug 3/17   

68 Portugal Cove Road, St John's, Newfoundland and Labrador A1B 2L9 Canada  
Telephone: +1 709 758 0913 Fax: +1 709 758 0927  www.rdc.org
Mr. Chris Gardner  
Chief Operating Officer  
Sequence BioInformatics Inc.  
30 Harvey Road, Suite 2  
St. John's, NL A1C 3G1

Dear Mr. Gardner:

Re: Technical Pilot Project (5405-2146-101) for Dan Brake

In response to the contract change for this project that was requested on February 23, 2018, I am pleased to approve this change regarding the R&D Proof of Concept award for Technical Pilot Project.

The following is a summary of the approved contract changes:

-㇇㇇㇇㇇ S.21(1)(b) of RDC Act

It is agreed that this approval does not affect the project scope or cost associated with this project.

If you have any questions or require additional information, please contact Bill Woolridge at 709-729-7123 or bwoolrid@gov.nl.ca.

Sincerely,

Ted Lomond  
Chief Executive Officer  

Date

Feb 23/18